NCCN Prostate 2.2020 Flashcards
To become an NCCN master.
A strong family history of prostate cancer consists of:
Brother or father or multiple family members diagnosed with prostate CA (NOT Grade Group I) at LESS THAN 60 YRS OLD OR who DIED from prostate CA
PROS-B
Family history criteria to prompt genetic testing:
- Strong family history
- Ashkenazi Jewish ancestry
- > = 3 cancers on same side of family, esp. diagnoses <= 50 yrs of age
Clinical/Pathologic Features:
Very low risk
ALL of the ff:
T1c AND Grade Group 1 AND PSA < 10ng/mL < 3 prostate biopsy fragments/cores positive, <= 50% cancer in each fragment/core AND PSA Density < 0.15 ng/mL/g
PROS-2
Clinical/Pathologic Features:
Low risk
ALL of the ff but does not qualify for low risk:
T1-T2a AND
Grade Group 1 AND
PSA < 10 ng/mL
PROS-2
Clinical/Pathologic Features:
Favorable intermediate
1 IRF and
Grade Group 1 or 2 and
< 50% biopsy cores positive
PROS-2
Clinical/Pathologic Features:
Unfavorable intermediate
2 or 3 IRFs and/or
Grade Group 3 and/or
>= 50% biopsy cores positive
PROS-2
Clinical/Pathologic Features:
High risk
T3a OR
Grade Group 4 or Grade Group 5 or PSA > 20ng/mL
PROS-2
Clinical/Pathologic Features:
Very high risk
T3b-T4 OR
Primary Gleason pattern 5 OR
>4 cores with Grade Group 4 or 5
PROS-2
Active surveillance definition
Actively monitoring the course of disease with the expectation to intervene with potentially curative therapy if the cancer progresses.
Active surveillance components
mpMRI and/or prostate biopsy to confirm candidacy for active surveillance
PSA every 6 mos
DRE every 12 mos
Repeat prostate biopsy every 12 mos
Repeat mpMRI every 12 mos
*No more often than, unless clinically indicated
PROS-3
Adverse features, post-RP, and treatment options if these are present:
- Positive margins
- Seminal vesicle invasion
- Extracapsular extension
- Detectable PSA
Treatment:
EBRT _+ ADT
OR
Observation
PROS-6
Observation definition
Monitoring the course of disease with expectation to deliver palliative therapy for the development of symptoms or change in PSA that suggests symptoms are imminent.
Palliative therapy = Palliative ADT
PSA nadir definition
NAY-dur
The lowest PSA value reached after RT.
PSA persistence and recurrence after RP
- Failure of PSA to fall to undetectable levels (persistence)
- Undetectable PSA after RP that increases on 2 or more determinations (PSA recurrence)
PSA persistence/recurrence after RT
PSA increase by 2 ng/mL or more above the nadir PSA
RTOG-ASTRO Phoenix
Genetic testing for germline variants should include:
MLH1 MSH2 MSH6 PMS2 (Lynch syndrome) BRCA1 BRCA2 ATM PALB2 CHEK2 HOXB13
Treatment options for:
Very low risk, life expectancy >=20 y
Active surveillance
EBRT or brachytherapy
RP
Treatment options for:
Very low risk, life expectancy 10-20 y
Active surveillance
Treatment options for:
Very low risk, life expectancy <10y
Observation
Treatment options for:
Low risk, life expectancy >= 10 y
Active surveillance (PREFERRED)
EBRT or brachytherapy
RP
Treatment options for:
Low risk, life expectancy <10 y
Observation
Treatment options for:
Favorable intermediate risk, life expectancy >=10 y
Active surveillance
EBRT or brachytherapy alone
RP _+ PLND if probability of LN mets >= 2%
Treatment options for:
Favorable intermediate risk, life expectancy < 10y
EBRT or brachytherapy alone
Observation (preferred)
Treatment options for:
Post-RP, positive LN mets, no adverse features
ADT (CATEGORY 1)
_+ EBRT (CATEGORY 2B)
OR
Observation
Treatment options for:
Unfavorable intermediate risk, >= 10 y life expectancy
RP_+PLND if predicted probability of LN mets _>2%
EBRT + ADT (4-6 mos)
or
EBRT + brachytherapy _+ ADT (4-6 mos)
PROS-6
Treatment options for:
Unfavorable intermediate, <10 y life expectancy
EBRT +ADT (4-6 mos)
or
EBRT + brachytherapy _+ ADT (4-6 mos)
Observation
PROS-6
Treatment options for:
High or very high risk, >5 y life expectancy
EBRT + ADT (1.5 - 3 y; category 1 ADT) + docetaxel (cat 1, for very high risk)
EBRT + brachytherapy + ADT (1-3 y; category 1 for ADT)
RP + PLND
PROS-7
Treatment options for:
High or very high risk, <= 5y and asymptomatic
Observation or ADT or EBRT
Initial management for:
PSA persistence/recurrence after RP
PSADT
Look for distant mets:
Bone imaging
Chest CT
Abdominal/pelvic CT or MRI
C-11 choline or F-18 fluciclovine PET/CT or PET/MRI
Prostate bed biopsy suggests local recurrence
If (-) distant mets/no imaging done: EBRT + ADT then wait for progression
If (+) mets: M1 na
PROS-11
Treatment options for:
M0, castration-naïve
Observation (preferred)
or
ADT
PROS-13
Define castration-naïve
Patients who are not on ADT at the time of progression
OR
have had neoadjuvant, concurrent, or adjuvant ADT as part of radiation therapy provided they have recoverede testicular function
Differentiate: high-volume vs. low-volume disease
High-volume: visceral mets and/or 4 or more bone mets with at least one mets beyond the pelvis or vertebral column
Treatment options for:
M1, castration-naïve
ADT with one of the following: Docetaxel 75 mg/m2 x 6 cycles (CAT 1) Abiraterone (CAT 1) Apalutamide (CAT 1) Enzalutamide (CAT 1)
Other: fine-particle abiraterone (cat 2b)
EBRT to the primary tumor for low-volume M1
or
ADT
PROS-13
Castrate levels of testosterone
< 50 ng/mL
Treatment options for:
M0, CRPC, PSADT >10 mos
Observation
or
Secondary hormone therapy
Treatment options for:
M0, CRPC, PSADT <=10 mos
Continue ADT to maintain serum levels of testosterone < 50 ng/dL
Apalutamide (Cat 1) or Darolutamide (Cat 1) or Enzalutamide (Cat 1 or Other secondary hormone therapy
PROS-14
Initial treatment options for:
M1CRPC
Metastatic biopsy of lesion: if it cannot be done - treat as adenocarcinoma;
MSI-H and dMMR testing;
Germline and tumor testing;
Continue ADT, maintain castrate levels of testosterone \+ Bone antiresorptive therapy: denosumab (cat 1) or zoledronic acid IF bone mets present OR Sipuleucel-T (cat 1) OR Palliative RT for painful bone mets OR Best supportive care
Systemic therapy options for M1CRPC, adenocarcinoma, FIRST LINE:
Category 1: Abiraterone Docetaxel Enzalutamide Sipuleucel-T Radium-223 for symptomatic bone mets
Not Cat 1:
Mitoxantrone for palliation
Fine-particle abiraterone
Other secondary hormone therapy
PROS-16
Systemic therapy options for M1CRPC, adenocarcinoma, who had prior therapy abiraterone/enzalutamide SECOND LINE:
Preferred:
Docetaxel (cat 1)
Sipuleucel-T (cat 1)
Radium-223 for symptomatic bone metastasis (cat 1)
Others:
Olaparib for HRRm
Pembrolizumab for MSI-H and dMMR (cat 2B)
Rucaparib for BRCAm
[if AR-V7 (+): use taxanes for increase OS]
PROS-16
Systemic therapy options for M1CRPC, adenocarcinoma, prior therapy docetaxel, SECOND LINE:
Abiraterone (cat 1)
Cabazitaxel (cat 1)
Enzalutamide (cat 1)
Olaparib for HRRm
Pembrolizumab for MSI-H and dMMR (cat 2B)
Rucaparib for BRCAm
Radium-223 for symptomatic bone mets
PROS-16
Category 1 FIRST LINE Systemic therapy options for:
M1CRPC, adenocarcinoma
Abiraterone Docetaxel Enzalutamide Sipuleucel-T Radium-223 for symptomatic bone mets
PROS-16
Category 1 SECOND LINE Systemic therapy options for:
M1CRPC, previous therapy with enzalutamide, abiraterone
Preferred:
Docetaxel (cat 1)
Sipuleucel-T
Radium-223 for symptomatic bone mets
Olaparib for HRRm
Category 1 SECOND LINE Systemic therapy options for:
M1CRPC, previous therapy with docetaxel
Abiraterone
Enzalutamide
Cabazitaxel
Radium-223 for symptomatic bone mets
PROS-16
What is the Will Rogers effect?
When the worst prognosis patients from one risk group move to the higher risk group, the average outcome of both risk groups will improve even if treatment has no impact on disease.
During active surveillance, cancer progression may have occurred if:
- Gleason Grade 4 or 5 on repeat biopsy
- Prostate CA found in a greater number of prostate biopsies or occupies a greater extent of prostate of prostate biopsy
PROS-D
Advantages of active surveillance (4):
- 2/3 of men eligible for active surveillance will avoid treatment
- Avoidance of possible side effects of definitive therapy that may be unnecessary
- Quality of life/normal activities potentially less affected
- Risk of unnecessary treatment of small, indolent cancers reduced
Disadvantages of active surveillance (3):
- Chance of missed opportunity for cure (but very low)
- 1/3 of men will require treatment
- Periodic follow-up mpMRI and prostate biopsies may be necessary
Advantages of observation:
Avoidance of possible side effects of unnecessary definitive therapy and early initiation and/or continuous ADT
Disadvantages of observation:
Risk of urinary retention or pathologic fracture without prior symptoms or concerning PSA levels
Boundaries of extended PLND:
Anterior: external iliac VEIN Posterior: pelvic floor Medial: bladder wall Lateral: pelvic sidewall Proximal: internal iliac ARTERY Distal: Cooper's ligament
Differentiate favorable and unfavorable intermediate in terms of IMAGING choices
Favorable: Bone imaging NOT recommended
Unfavorable: Bone imaging recommended if T2 and PSA > 10 ng/mL